World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
26560
World Ranking
13696
National Ranking
6956

Overview

Luis Fayad is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on the field of Medicine, with a significant emphasis on Oncology, Pathology and Forensic Medicine, Genetics, Immunology, and Molecular Biology.

The scientist's main areas of work include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Immune Cell Function and Interaction

Fayad has contributed extensively to academic publications, appearing frequently in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Leukemia & Lymphoma, and International Journal of Radiation Oncology*Biology*Physics.

Their recent notable papers include:

  • "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas," 2020, Nature Medicine
  • "Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma," 2020, Blood Advances
  • "Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma," 2021, Blood
  • "A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy," 2023, Nature Medicine
  • "NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021," 2021, Journal of the National Comprehensive Cancer Network

The scientist frequently collaborates with a group of co-authors, including:

  • Sattva S. Neelapu
  • Jason R. Westin
  • Loretta J. Nastoupil
  • Christopher R. Flowers
  • Sairah Ahmed

Best Publications

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

    Jason R Westin;Fuliang Chu;Min Zhang;Luis E Fayad

  • Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

    Catherine M. Bollard;Catherine M. Bollard;Stephen Gottschalk;Stephen Gottschalk;Vicky Torrano;Vicky Torrano;Oumar Diouf;Oumar Diouf

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

    Yasuhiro Oki;Mansoor Noorani;Pei Lin;Richard E. Davis

  • Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

    Hagop M. Kantarjian;Deborah A. Thomas;Jeffrey L. Jorgensen;Elias Joseph Jabbour

  • Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients

    Roberto N. Miranda;Tariq N. Aladily;H. Miles Prince;Rashmi Kanagal-Shamanna

  • Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.

    Qing Deng;Guangchun Han;Nahum Puebla-Osorio;Man Chun John Ma

  • AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

    David Sanghyun Hong;Razelle Kurzrock;Youngsoo Kim;Richard Woessner

  • Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

    Jonathan W. Friedberg;Philip Cohen;Ling Chen;K. Sue Robinson

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis

    Eleni Diamandidou;Maria Colome-Grimmer;Luis Fayad;Madeleine Duvic

  • Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.

    Luis E Fayad;Michael J. Keating;James M. Reuben;Susan O'Brien

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

    Jorge E. Romaguera;Luis E. Fayad;Lei Feng;Kimberly Hartig

  • Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

    Jorge E. Romaguera;L. Jeffrey Medeiros;Frederick B. Hagemeister;Luis E. Fayad

  • Benefit of Consolidative Radiation Therapy in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP Chemotherapy

    Jack Phan;Ali Mazloom;L Jeffrey Medeiros;Tony G. Zreik

Frequent Co-Authors

Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Peter McLaughlin
Peter McLaughlin The University of Texas MD Anderson Cancer Center
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Andre Goy
Andre Goy Hackensack University Medical Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While pursuing a traditional medical degree is a popular path, there are several related online degrees that can lead to promising healthcare careers in the USA. For those interested in health leadership, exploring the cheapest online healthcare administration degree programs can open doors to administrative and management roles in hospitals and clinics.

Advancing further, earning an MHA is a smart move for career growth. Be sure to consider the mha degree cost to find affordable, accredited programs that fit your budget.

For registered nurses aiming for a higher degree, the best online bsn to dnp programs offer a flexible path to advanced practice and leadership roles.

If pharmacy interests you, consider researching accredited online pharmacist programs that combine affordability with quality education, allowing you to study at your own pace.

With a range of cost-effective online health programs available, finding the right path for your career goals in medicine and healthcare is easier than ever.

Best Scientists Citing Luis Fayad

Trending Scientists